The impact of external reference pricing on pharmaceutical costs and market dynamics
© 2023 The Author(s)..
Growth in the cost of prescription drugs in the US has generated significant interest in the use of external reference pricing (ERP) to tie prices paid for drugs to those in other countries. We used data from the Pricentric ONE™ database, an international drug pricing database, to examine product launch timing, launch price, and price changes from January 2010 - October 2021 in both ERP and non-ERP settings, with a focus on 100 high-priced drugs of interest to Medicare and Medicaid. We found that ERP policies were associated with a 73% reduction in the likelihood of drug launch within 9 months of regulatory approval relative to non-ERP settings. In addition, while ERP was associated with statistically significant reductions in annual drug price changes, such policies did not impact launch price. In addition, no single ERP feature (e.g., number of countries referenced, ERP calculation) was materially associated with the outcomes of interest. We conclude that ERP policies do not appear to impact drug launch price and may delay access to new therapies, raising questions about the utility of such policies in the US and potential consequences abroad.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Health policy OPEN - 4(2023) vom: 23. Dez., Seite 100093 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Voehler, Dominic [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cost-effectiveness |
|---|
| Anmerkungen: |
Date Revised 03.07.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.hpopen.2023.100093 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358851661 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358851661 | ||
| 003 | DE-627 | ||
| 005 | 20231226075627.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.hpopen.2023.100093 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM358851661 | ||
| 035 | |a (NLM)37383884 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Voehler, Dominic |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The impact of external reference pricing on pharmaceutical costs and market dynamics |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.07.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Author(s). | ||
| 520 | |a Growth in the cost of prescription drugs in the US has generated significant interest in the use of external reference pricing (ERP) to tie prices paid for drugs to those in other countries. We used data from the Pricentric ONE™ database, an international drug pricing database, to examine product launch timing, launch price, and price changes from January 2010 - October 2021 in both ERP and non-ERP settings, with a focus on 100 high-priced drugs of interest to Medicare and Medicaid. We found that ERP policies were associated with a 73% reduction in the likelihood of drug launch within 9 months of regulatory approval relative to non-ERP settings. In addition, while ERP was associated with statistically significant reductions in annual drug price changes, such policies did not impact launch price. In addition, no single ERP feature (e.g., number of countries referenced, ERP calculation) was materially associated with the outcomes of interest. We conclude that ERP policies do not appear to impact drug launch price and may delay access to new therapies, raising questions about the utility of such policies in the US and potential consequences abroad | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cost-effectiveness | |
| 650 | 4 | |a Drug pricing | |
| 650 | 4 | |a External reference pricing | |
| 650 | 4 | |a International reference pricing | |
| 650 | 4 | |a Value-based pricing | |
| 700 | 1 | |a Koethe, Benjamin C |e verfasserin |4 aut | |
| 700 | 1 | |a Synnott, Patricia G |e verfasserin |4 aut | |
| 700 | 1 | |a Ollendorf, Daniel A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Health policy OPEN |d 2020 |g 4(2023) vom: 23. Dez., Seite 100093 |w (DE-627)NLM314086544 |x 2590-2296 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2023 |g day:23 |g month:12 |g pages:100093 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.hpopen.2023.100093 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2023 |b 23 |c 12 |h 100093 | ||